Based on RNS issued during last year we can expect, 1. Significant increase in revenues for second half of year. 2. Licensing deals with Future Processing in Poland for new software products. 3. Developments on MOU with Allied Medical for integration of Texrad. 4.News on sales of Texrad research versions in Asia. 5.Confirmation of CE Mark for Texrad lung. 6. Progress on CE Mark for other Texrad products like liver etc. 7. Information on commercial arrangements with global CT/MRI manufacturers 're integration of Texrad lung. 8. Indication of progress with ex directors disposal of holdings. 9. Indication of strategic direction going forward 're development of broad suite of Texrad products. Plenty to look forward to!
Afternoon guys. Good to see they are spending some marketing budget on sponsorship In big growth area. Balaji was part of UK trade mission a few months ago and maybe we are now bearing some fruit. It's positive anyway and radiologists globally seem to be preparing for advanced imaging as a standard. If we still lead the way as Balaji suggests then the omens are good. Balaji has become so respected globally with his Texrad development he deserves all the success that comes his way.
Hi mate. Glad it's not my bank details you want! mikeseppings@gmail.com
Also how are negotiations proceeding with ex directors on orderly sale of large number of shares? Tom Charlton has only agreed not to sell until November, it creeps ever closer. Trevor Brown has already started to reduce holding. The potential overhang is detrimental to any realistic value in company going forward. So many questions!
Small addition this morning at 1.96. Hope you safe and well Botak.
Thanks Bob for sharing. Because of my nature I regard this as positive and I expect the mother of all RNS in due course! The annual revenue for Year ending May 2017 have already been advised as significantly ahead of previous year.
Gee Botak, that looks a concern for you and yours. Hope you stay safe, puts our little investment into perspective. The only eruption we need is in FDBK share price. Hope danger passes...
I am expecting positive news. The Director appointment and fundraising, which brought significant equity into the company 5 months ago was expected to enable rapid development of commercial deals and new product development. We should get information on how this equity is being spent very soon! Enjoy your weekend everyone, glorious day here in North Norfolk.
Board seem unable or reluctant to update shareholders with significant positive news hence share price reaction. Although CE Mark is crucial for Texrad Lung it is no more so than a negotiated agreement for ex directors to obtain an orderly sale of shares, should they wish to do so. It's always difficult as a shareholder to see profits diminish and I regularly spend time revisiting research and developments including announcements over past three years. The spin off company FBDU is being driven by our ex Director and major shareholder Trevor Brown and they seem to be making some good progress with our licenced product. We will also receive revenues from sales going forward. I don't think we will wait much longer for some news, we received a trading update at this time last year and the board have a responsibility to deliver update, good or otherwise. Stay patient everyone.
I picked up more today and remain convinced of the Texrad product, hopefully soon to become a suite of products available globally on leading manufacturers of CT scanners. I am however known by family and friends as a supreme optimist! Not long now!! Good luck everyone.
Sell at 2.25, buy at 2.27. Advertised prices 2.25 across the board!
Hi Botak, Bob, Don't disagree on any points and CE Mark for Lung was not expected to be a problem, in fact looking back at company emails a Director confirmed in May process, timings and relative ease of it all! However they clearly underestimated the work involved and its unlikely given the complexities of Texrad algorithms et al that new recruits with technical or IT skills could have completed task more quickly The work is being carried out by a small team of experienced Texrad specialists and we have to wait and see. Always a problem when a company raises expectations and fails to deliver on time. I do believe the wait will be extremely worthwhile for all.
Morning everyone, had some contact from Director this morning. Briefly, key points as follows, -real progress being made on product development and Technical Dossiers necessary for CE Mark for Texrad Lung. - the delay is caused by constraints which exist in a very small team (and organisation). -all work is geared toward clinical commercialization of product. -distribution discussions and commercial sales expertise strengthening. - revenues being maintained by high interest AND orders for Texrad research. Understand need for communications and will report on developments as milestones reached. We are a very very small company and things take time. I feel reassured. Mike Hayball is clearly working very hard on the technical stuff as well as fielding questions from shareholders.
Morning everyone. Feedback website contact page "always interested" and "contact us". Good to know, I have made contact twice very recently, unfortunately your lack of response suggests you don't appear very interested at all. Previous directors great at response and very transparent, currently appear rude and comms very poor. Hope we get some improvements soon. Enjoy weekend.
Sorry, not homepage, contact page seems newer and changed.
Have asked some direct but polite questions of the company this morning via email. Will let you know of any feedback! Interesting new homepage on website, think they may be getting the message.
Great story Elartu, your granddaughter helped you with a profitable piece of business!
Hi Chaz, If you look at trades since beginning of August all are listed red as sells, many are buys. I know as I have been buying and have never paid more than advertised sell price! What this means... haven't a clue!!
Botak for sharing. You sound more upbeat!!
Cheers Fish, well done for trying! The delay and uncertainty about current progress leads to all of these questions. We must not speculate though rather let them get their heads down and deliver.